ECS signs UK Distribution and Manufacturing Agreement with Curaleaf Laboratories
ECS Botanics Holdings Ltd (ASX:ECS) has entered a Distribution and Manufacturing Agreement with Rokshaw Limited trading as Curaleaf Laboratories, to support the launch and distribution of ECS-branded medicinal cannabis products in the United Kingdom. Initial supply is targeted for November 2026, subject to completion of product registrations, import and export permits and other applicable regulatory requirements.
The agreement initially covers six ECS-branded Australian-grown medicinal cannabis flower products. All are intended to be supplied in 10g ECS-branded pouches using UK-compliant packaging and labelling.
The agreement extends ECS’s branded product strategy into another international market, following the launch of its product brand through Nimbus in Germany. It also gives ECS access to established local manufacturing, regulatory and distribution capabilities without requiring ECS to establish its own downstream infrastructure in the UK.
When big ASX news breaks, our subscribers know first
How the UK distribution model works
Consignment structure and revenue exposure
ECS will supply Australian-grown medicinal cannabis flower in bulk to Curaleaf Laboratories in the UK. Curaleaf Laboratories will undertake local manufacturing into the ECS-branded pouches in accordance with applicable EU GMP, GDP and regulatory requirements. It will then distribute the finished products through its own and third-party distribution channels.
The agreement establishes a consignment-based commercial model. ECS retains ownership of product until it is sold by Curaleaf Laboratories or paid for.
ECS will receive an agreed proportion of the net sales price, which the announcement describes as providing direct exposure to UK product sell-through. The percentage has not been disclosed.
Key agreement terms
The announcement sets out the following material terms.
| Term | Detail |
|---|---|
| Parties | ECS Botanics MC Pty Ltd and Rokshaw Limited trading as Curaleaf Laboratories |
| Territory | United Kingdom, including the Channel Islands and Isle of Man |
| Term | Initial term of **two years**, with automatic renewals for subsequent **two-year** periods unless terminated in accordance with its terms |
| Exclusivity | Non-exclusive |
| Minimum commitments | None (no minimum purchase or revenue commitments) |
- Following the first anniversary, either party may terminate the agreement for convenience by providing at least three months’ written notice.
Because product volumes and revenue will depend on market demand and sell-through, ECS stated it does not consider it appropriate to provide revenue guidance at this stage.
Building value through ECS-owned and licensed brands
Bulk wholesale flower is sold as a raw product, typically at lower margins. Branded finished products are packaged, labelled and marketed under a company’s own name, which can allow a producer to capture more value from the same crop.
ECS stated that its branded product strategy has become an increasingly important driver of the business. The company is focused on capturing greater value from the products it cultivates and manufactures rather than relying predominantly on lower-margin wholesale channels.
Branded B2C sales reached 71% of total quarterly revenue in Q3 FY26, up 55% year-on-year, showing how far the shift away from lower-margin wholesale channels has already progressed.
In the UK, the product must be manufactured in line with EU GMP (Good Manufacturing Practice) and GDP (Good Distribution Practice) requirements. Under the agreement, a local partner, Curaleaf Laboratories, undertakes that manufacturing into pouches and handles distribution.
According to the announcement, Curaleaf Laboratories operates an MHRA-approved medical cannabis manufacturing facility and has been part of Curaleaf International since 2019. The announcement also states that it was the first manufacturer of full spectrum medical cannabis in the UK. ECS has maintained a long-standing commercial relationship with the company.
Nan-Maree Schoerie, Managing Director, ECS Botanics
“The structure with Curaleaf Laboratories allows ECS to retain exposure to the value generated when our products are sold in the UK, while leveraging Curaleaf’s established local manufacturing and distribution infrastructure.”
Jonathan Hodgson, Curaleaf International UK Managing Director
“By combining ECS Botanics’ expertise in cultivation and pharmaceutical-grade production with Curaleaf Laboratories’ UK manufacturing, regulatory and supply-chain capabilities, we can deliver branded products to the UK market with the standards of quality and reliability that patients and prescribers rightly expect.”
Next steps and what to watch
The announcement points to several milestones for investors to track:
- Completion of product registrations
- Import and export permits
- Initial supply, targeted for November 2026
- Sell-through and volume outcomes, which may be disclosed in future reporting
The near-term focus is regulatory execution. With no minimum purchase or revenue commitments, the revenue contribution from the UK agreement is not quantified, and ECS has not provided guidance.
Investors weighing how much the UK agreement could matter may find our detailed coverage of ECS’s H1 FY26 profit turnaround useful, as it walks through the EBITDA growth, the completed infrastructure build and the rising branded revenue mix behind the company’s current financial position.
Schoerie summarised the immediate priority:
Nan-Maree Schoerie, Managing Director, ECS Botanics
“Our immediate focus is now on completing the required registrations and permits, with initial supply targeted for November.”
Don’t Miss the Next Healthcare Breakout
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get healthcare announcements in your inbox the moment they break and stay ahead of the market.